[8-K] CUMBERLAND PHARMACEUTICALS INC Reports Material Event

Cumberland Pharmaceuticals Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in patients with Duchenne muscular dystrophy (DMD).

Rhea-AI Filing Summary

Cumberland Pharmaceuticals Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in patients with Duchenne muscular dystrophy (DMD). This status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. Cumberland furnished a press release with additional details as an exhibit to this report.

Insights

Biopharma regulatory analyst

FDA Fast Track status is a meaningful, potentially value-enhancing regulatory milestone.

The company states that the U.S. Food and Drug Administration granted Fast Track Designation to its novel oral therapy for a fatal form of heart disease in Duchenne muscular dystrophy patients. Fast Track is reserved for serious conditions with unmet medical need.

This designation can permit more frequent FDA interactions and eligibility for expedited review pathways, which may shorten development and review time if supporting data are positive. Actual outcomes will depend on future clinical results and regulatory decisions described in subsequent disclosures.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 05:20 PM Learn about SEC filing dates

0001087294false00010872942026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

February 4, 2026 (February 4, 2026)

Date of Report (date of earliest event reported)

CUMBERLAND PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Tennessee			001-33637						62-1765329
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)

1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203

(Address of Principal Executive Offices)

(615) 255-0068

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, no par value			CPIX			NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01     Other Events

On February 4, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients.

A copy of the release is furnished as Exhibit 99.1.

Exhibit No.						Description
99.1						Press release dated February 4, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

Dated: February, 2025

By:

/s/ John Hamm

John Hamm

Chief Financial Officer